HK49079A - A process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtained thereby - Google Patents

A process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtained thereby

Info

Publication number
HK49079A
HK49079A HK490/79A HK49079A HK49079A HK 49079 A HK49079 A HK 49079A HK 490/79 A HK490/79 A HK 490/79A HK 49079 A HK49079 A HK 49079A HK 49079 A HK49079 A HK 49079A
Authority
HK
Hong Kong
Prior art keywords
components
acetals
steroid
separation
stereoisomeric mixtures
Prior art date
Application number
HK490/79A
Other languages
English (en)
Original Assignee
Bofors Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bofors Ab filed Critical Bofors Ab
Publication of HK49079A publication Critical patent/HK49079A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HK490/79A 1972-05-19 1979-07-19 A process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtained thereby HK49079A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (OSRAM) 1972-05-19 1972-05-19

Publications (1)

Publication Number Publication Date
HK49079A true HK49079A (en) 1979-07-27

Family

ID=20269238

Family Applications (1)

Application Number Title Priority Date Filing Date
HK490/79A HK49079A (en) 1972-05-19 1979-07-19 A process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtained thereby

Country Status (17)

Country Link
US (1) US3928326A (OSRAM)
JP (1) JPS547794B2 (OSRAM)
BE (1) BE799728A (OSRAM)
CA (1) CA1003402A (OSRAM)
CY (1) CY1012A (OSRAM)
DE (1) DE2323216C3 (OSRAM)
DK (1) DK133249C (OSRAM)
FI (1) FI50711C (OSRAM)
FR (1) FR2185406B1 (OSRAM)
GB (1) GB1428416A (OSRAM)
HK (1) HK49079A (OSRAM)
IL (1) IL42154A (OSRAM)
KE (1) KE2969A (OSRAM)
NL (1) NL175917C (OSRAM)
SE (1) SE378110B (OSRAM)
SU (1) SU468408A3 (OSRAM)
ZA (1) ZA732956B (OSRAM)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188581C (nl) * 1974-07-15 1992-08-03 Akzo Nv Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
ZA763131B (en) * 1975-05-27 1978-01-25 Syntex Inc Use of flunisolide to treat respiratory diseases
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
ES2137353T3 (es) * 1993-01-08 1999-12-16 Astra Ab Nuevos derivados esteroides especificos del colon o del ileon.
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
JP2007504123A (ja) * 2003-08-29 2007-03-01 ランバクシー ラボラトリーズ リミテッド Ｉｖ型ホスホジエステラーゼの阻害剤
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
CN1942470A (zh) 2004-04-09 2007-04-04 默克公司 Akt活性抑制剂
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
AU2006305619A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
CA2626628A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
MX2009003100A (es) * 2006-09-22 2009-05-11 Ranbaxy Lab Ltd Inhibidores de fosfodiesterasa tipo iv.
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
DK2099442T3 (en) 2006-12-26 2015-02-16 Pharmacyclics Inc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
HRP20120361T1 (hr) * 2007-03-14 2012-05-31 Ranbaxy Laboratories Limited DERIVATI PIRAZOLO[3,4-b]PIRIDINA KAO INHIBITORI FOSFODIESTERAZE
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
CN102482318B (zh) * 2009-09-11 2015-11-25 奇斯药制品公司 异噁唑烷衍生物
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
CN104945382B (zh) 2009-10-14 2020-02-07 默沙东公司 提高p53活性的取代的哌啶和其用途
WO2011097594A2 (en) 2010-02-08 2011-08-11 Kinagen, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP3587574B1 (en) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2699568A1 (en) 2011-04-21 2014-02-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
NZ621221A (en) 2011-09-13 2016-07-29 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
EP2888255B1 (en) 2012-08-24 2018-07-18 Board of Regents, The University of Texas System Heterocyclic modulators of hif activity for treatment of disease
US9155747B2 (en) * 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
MX373639B (es) 2012-12-20 2020-05-04 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3475275B1 (en) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
KR20190074310A (ko) 2016-11-08 2019-06-27 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 단백질-접합체
IL270594B2 (en) 2017-05-18 2024-06-01 Regeneron Pharma Cyclodextrin protein drug conjugates
CN111601619A (zh) 2017-11-07 2020-08-28 里珍纳龙药品有限公司 用于抗体药物偶联物的亲水性连接体
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
MA50259A1 (fr) 2018-01-08 2021-07-29 Regeneron Pharma Stéroïdes et leurs conjugués-anticorps
JP7590871B2 (ja) 2018-05-09 2024-11-27 レゲネロン ファーマシューティカルス，インコーポレーテッド 抗ｍｓｒ１抗体及びその使用方法
KR20210046009A (ko) 2018-08-07 2021-04-27 머크 샤프 앤드 돔 코포레이션 Prmt5 억제제
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP4076459A4 (en) 2019-12-17 2023-12-20 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP4077282A4 (en) 2019-12-17 2023-11-08 Merck Sharp & Dohme LLC Prmt5 inhibitors
CA3265870A1 (en) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Pharmaceutical compositions based on topoisomerase-1 inhibitors derived from Exatecan, and their uses
KR20250079227A (ko) 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
IL321395A (en) 2022-12-14 2025-08-01 Merck Sharp & Dohme Llc Auristatin cargo-linkers, pharmaceutical compounds, and their uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae

Also Published As

Publication number Publication date
DE2323216C3 (de) 1978-06-22
NL175917C (nl) 1985-01-16
FI50711B (OSRAM) 1976-03-01
ZA732956B (en) 1974-04-24
JPS547794B2 (OSRAM) 1979-04-10
US3928326A (en) 1975-12-23
DK133249B (da) 1976-04-12
NL7306979A (OSRAM) 1973-11-21
IL42154A0 (en) 1973-07-30
CY1012A (en) 1979-11-23
SU468408A3 (ru) 1975-04-25
IL42154A (en) 1976-12-31
DE2323216A1 (de) 1973-11-29
BE799728A (fr) 1973-09-17
NL175917B (nl) 1984-08-16
DE2323216B2 (de) 1977-11-03
DK133249C (da) 1976-09-13
FR2185406A1 (OSRAM) 1974-01-04
AU5525273A (en) 1974-11-07
JPS4941379A (OSRAM) 1974-04-18
SE378110B (OSRAM) 1975-08-18
CA1003402A (en) 1977-01-11
FR2185406B1 (OSRAM) 1976-12-31
FI50711C (fi) 1976-06-10
GB1428416A (en) 1976-03-17
KE2969A (en) 1979-07-20

Similar Documents

Publication Publication Date Title
HK49079A (en) A process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtained thereby
YU35896B (en) Process for obtaining steroids
AU7769591A (en) Improved isotope separation process
GB1367830A (en) Processes and materials for making photoresists
CA920319A (en) Method of expanding a pliable material
PH11742A (en) Process for the separation of isoprene
CA1004043A (en) Separation of uranium isotopes
ZA717190B (en) Process for the preparation of phenol-resin foam materials
KR780000672B1 (en) Method of manufacturing steroids of the pregnane series
CA985482A (en) Process for the production of uranium hexafluoride
ZA708507B (en) New 21-mercapto-steroids of the pregnane series and a process for their manufacture
PH11175A (en) Process for the preparation of seliceous ashes and apparatus therefor
CA1015670A (fr) Procede pour l'enrichissement d'un melange gazeux en l'un au moins de ses constituants
AU475485B2 (en) Process forthe preparation of steroids ofthe prednisolone series
AU6217373A (en) Flotation separation process
PH11209A (en) A process for the separation of hydrophobic solid particles from mixtures thereof
ZA735374B (en) Separation process
AU478324B2 (en) A process for the separation of stereoisomeric mixtures into their components and components obtained hereby
IL41600A (en) A process for the preparation of alpha-6-deoxytetracyclines
IL26717A (en) Process for the production of acetals of beta-haloaldehydes
CA890949A (en) Separating mixtures of stereoisomeric diaminodicyclohexylalkane
IL42226A0 (en) A process for the preparation of eburnamonines
GB1439804A (en) Method and apparatus for producing at a distance a representation of the path of a point of a structure
CA892477A (en) Process of beneficiation
ZM16573A1 (en) Process for the separation of nickel values